Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14434430 | 0.81 | NOS2 (0.42) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL22863898 | 0.81 | NOS2 (0.42) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL29009767 | 0.80 | FFAR1 (0.41) | SMN1; SMN2 | |
| SCHEMBL581364 | 0.79 | CCNB2 (0.35) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL22138663 | 0.77 | NOS2 (0.33) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL25191542 | 0.76 | GAA (0.40) | TAAR1GAASMN1; SMN2 | |
| SCHEMBL22863922 | 0.76 | NOS3 (0.38) | TAAR1GAASMN1; SMN2 | |
| SCHEMBL25199133 | 0.76 | LOXL2 (0.39) | TAAR1GAASMN1; SMN2 | |
| SCHEMBL29009936 | 0.75 | FFAR1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL25196993 | 0.74 | LOXL2 (0.38) | TAAR1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991985-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-06-13 | — | — | EP | disclosed |
| EP-2991985-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-06-13 | — | — | EP | disclosed |
| EP-2991985-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-9181272-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181272-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181272-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| WO-2014179186-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179186-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-06 | — | — | WO | disclosed |
| US-20140323468-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323468-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323468-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP21A2, REN | CCNB2 1535/4885CDK1 422/4885CCNB1 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.